Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of AL002 in healthy adults and adults with mild to moderate Alzheimer's disease
NL-OMON50153Phase 1Active, not recruiting
- Sponsor
- Alector
- Start
- Feb 2020
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AL002 in Alzheimer's disease (AD) (3 arms), sponsored by Alector. Primary endpoints: Serious adverse events and adverse events of special interest, Dose limiting adverse events and 12 more. Started Feb 2020; status: active, not recruiting.
02
Drugs
AL002
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON50153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50153.